NATCO Pharma has secured approval for generic Everolimus tablets for oral suspension. The company’s marketing partner for the ANDA, Breckenridge Pharmaceutical plans to launch it in the US market immediately.
Global Pharma | 30/01/2025 | By Abha
Brenntag Pharma Extends Partnership with Citribel for Citric Acids and Citrates Pharma Excipients
In addition to the longtime cooperation on the Pharma markets of France, Spain, Germany and Benelux, Citribel is now offered to Brenntag Pharma customers in Israel, Turkey and South Africa (RSA).
Global Pharma | 29/01/2025 | By Aishwarya
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of USD 250 Million
The addition of Evergreen’s scalable manufacturing capabilities and infrastructure enhances Lantheus’ ability to meet the complex demands of radiopharmaceutical development and production.
Global Pharma | 29/01/2025 | By Aishwarya
Cold Chain Technologies and Tower Cold Chain Achieve Major Sustainability Milestones
The integration of Tower’s expertise in reusable temperature-controlled logistics with CCT’s wide portfolio of solutions and services has led to expanded product offerings and greater innovation.
Global Pharma | 29/01/2025 | By Aishwarya
Lantern Pharma Launches Innovative AI-Powered Module to Advance ADC Development for Cancer
The global ADC market is projected to reach USD 30.4 billion by 2028, growing at a CAGR of 41.7 percent, with several recently approved ADCs achieving blockbuster status with annual sales exceeding USD 1 billion.
Global Pharma | 28/01/2025 | By Aishwarya
This innovation provides oncologists with real-time visual evidence of chemotherapy drugs' effectiveness on a patient's tumor cells, derived from tissue biopsies or blood.
Global Pharma | 28/01/2025 | By Manvi
Curiox Biosystems Rolls Out Curiox C- Free Pluto ALPHA
The Curiox C- Free Pluto ALPHA replaces traditional centrifuge-based methods, offering a low-maintenance solution that eliminates bulky hardware.
Global Pharma | 27/01/2025 | By Aishwarya
Biocon's S&P Global ESG Score Improves to 69 for 2024, Up by 6 Points from 2023
Biocon Ltd., a global biopharmaceutical company, achieved a 6-point rise in its S&P Global ESG Score to 69 in 2024, ranking in the 98th percentile among biotechnology peers, with standout scores in Environmental (76), Social (74), and Governance (62) dimensions.
Global Pharma | 27/01/2025 | By Manvi
Zydus's Chairman Pankaj R Patel Conferred with Padma Bhushan
With a Masters in Pharmaceutics and Pharmaceutical Technology from the L.M. College of Pharmacy and an alumni of the Indian Institute of Management (IIM), Ahmedabad, he was always driven by a passion to become a pharma entrepreneur.
Global Pharma | 27/01/2025 | By Aishwarya
AstraZeneca To Invest CAD 820 Mn in Canada to Boost Clinical Delivery Sector
New investment in Canada will contribute to AstraZeneca’s global ambition to achieve USD80 billion in Total Revenue and to bring 20 new medicines to patients around the world by 2030 of which eight new medicines have been delivered to date.
Global Pharma | 27/01/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy